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Abstract: AIMS The post-approval MELODY Registry aimed to obtain multicentre registry data after
transcatheter pulmonary valve implantation (TPVI) with the Melody™ valve (Medtronic plc.) in a large-
scale cohort of patients with congenital heart disease (CHD). METHODS AND RESULTS Retrospective
analysis of multicentre registry data after TPVI with the Melody™ valve. Eight hundred and forty-five
patients (mean age: 21.0 ± 11.1 years) underwent TPVI in 42 centres between December 2006 and
September 2013 and were followed-up for a median of 5.9 years (range: 0-11.0 years). The composite
endpoint of TPVI-related events during follow-up (i.e. death, reoperation, or reintervention >48 h after
TPVI) showed an incidence rate of 4.2% per person per year [95% confidence interval (CI) 3.7-4.9].
Transcatheter pulmonary valve implantation infective endocarditis (I.E.) showed an incidence rate of
2.3% per person per year (95% CI 1.9-2.8) and resulted in significant morbidity and in nine deaths. In
multivariable Cox proportional hazard models, the invasively measured residual right ventricle (RV)-to-
pulmonary artery (PA) pressure gradient (per 5 mmHg) was associated with the risk of the composite
endpoint (adjusted hazard ratio: 1.21, 95% CI 1.12-1.30; P < 0.0001) and the risk of TPVI I.E. (adjusted
hazard ratio: 1.19, 95% CI 1.07-1.32; P = 0.002). Major procedural complications (death, surgical, or
interventional treatment requirement) occurred in 0.5%, 1.2%, and 2.0%, respectively. Acutely, the RV-
to-PA pressure gradient and the percentage of patients with pulmonary regurgitation grade >2 improved
significantly from 36 [interquartile range (IQR) 24-47] to 12 (IQR 7-17) mmHg and 47 to 1%, respectively
(P < 0.001 for each). CONCLUSION The post-approval MELODY Registry confirms the efficacy of TPVI
with the Melody™ valve in a large-scale cohort of CHD patients. The residual invasively measured RV-
to-PA pressure gradient may serve as a target for further improvement in the composite endpoint and
TPVI I.E. However, TPVI I.E. remains a significant concern causing significant morbidity and mortality.
DOI: https://doi.org/10.1093/eurheartj/ehz201
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Aims  The post-approval MELODY Registry aimed to obtain multicentre registry data after 
transcatheter pulmonary valve implantation (TPVI) with the Melody  valve (Medtronic plc.) 
in a large-scale cohort of patients with congenital heart disease (CHD). 
Methods and results  Retrospective analysis of multicentre registry data after TPVI with the 
Melody  valve. 845 patients (mean age: 21.0±11.1 years) underwent TPVI in 42 centres 
between 12/2006 and 09/2013 and were followed-up for a median of 5.9 years (range: 0 to 11.0 
years). The composite endpoint of TPVI-related events during follow-up (i.e. death, reoperation 
or reintervention >48h after TPVI) showed an incidence rate of 4.2% per person per year (95% 
CI 3.7 4.9). TPVI infective endocarditis showed an incidence rate of 2.3% per person per year 
(95% CI 1.9 2.8) and resulted in significant morbidity and in 9 deaths. In multivariable Cox 
proportional hazard models, the invasively measured residual RV-to-PA pressure gradient (per 
5 mmHg) was associated with the risk of the composite endpoint (adjusted hazard ratio: 1.21, 
95% CI 1.12 1.30; P < 0.0001) and the risk of TPVI infective endocarditis (adjusted hazard 
ratio: 1.19, 95% CI 1.07 1.32; P = 0.002).  Major procedural complications (death, surgical or 
interventional treatment requirement) occurred in 0.5, 1.2, and 2.0%, respectively. Acutely, the 
right ventricle (RV)-to-pulmonary artery (PA) pressure gradient and the percentage of patients 
with pulmonary regurgitation grade >2 improved significantly from 36 (interquartile range 24-
47) to 12 (interquartile range 7-17) mmHg and 47 to 1%, respectively (P < 0.001 for each). 
Conclusions  The post-approval MELODY Registry confirms the efficacy of TPVI with the 
Melody  valve in a large-scale cohort of CHD patients. The residual invasively measured RV-
to-PA pressure gradient may serve as a target for further improvement in the composite 
endpoint and TPVI infective endocarditis. However, TPVI infective endocarditis remains a 








































































































































Transcatheter pulmonary valve implantation (TPVI) plays an important role within current 
treatment strategies for patients with congenital heart disease (CHD) and right ventricular 
outflow tract (RVOT) dysfunction1-9. RVOT dysfunction frequently occurs in these patients 
because of the limited lifespan of the material that was used during surgical repair.  
Currently, two balloon-expandable devices are available for TPVI: the Melody  valve 
(Medtronic plc, Ireland; CE-mark approval in 2006) and the SAPIEN XT (Edwards 
Lifesciences LLC, USA; FDA-approval in 2017). The devices have different specifications 
related  mm; SAPIEN XT: 20, 
23, 26 and 29 mm). 
The post-approval MELODY Registry aimed to obtain multicentre registry data after 
transcatheter pulmonary valve implantation (TPVI) with the Melody  valve  in a large-scale 





































































The post-approval MELODY Registry is an investigator-initiated, multicentre registry after 
TPVI with the Melody  valve outside the United States of America. Participating centres were 
approached during Melody  valve implanters meetings in Europe, regardless of the implanting 
physician´s level of past experience with TPVI. This strategy was adopted to achieve a large 
number of included patients and to allow for an assessment of observational data obtained in 
routine clinical practice. Overall, 42 cardiac centres contributed data of patients who received 
TPVI with the Melody  valve after CE-mark approval.  
In this study, patients were registered retrospectively. Firstly, study centres submitted 
anonymized data on patient
position during the study period (n = 1,080). Secondly, during computerized data management 
that was performed by the Coordination Center of Clinical Studies (KKS, Charité University 
Medicine Berlin), specified exclusion criteria were applied to allow for a consistent dataset that 
would be amenable for further statistical analysis (Supplemental Figure 1). Thus, 845/1,080 
datasets (78.2%) were included for analysis.   
The study adhered to international rules for scientific studies and the Helsinki principles. 
Consent was given by patients and/or parents/guardians as appropriate. The institutional review 
board or ethics committee at participating centres approved the submission of data. The events 
and values collected were site reported, and there were no core laboratories. The coordinating 
centre of the MELODY Registry was the German Heart Institute Berlin, Germany, where the 
data were collected and analyzed. The decision to undergo TPVI with the Melody  valve was 



































































General inclusion and exclusion criteria for TPVI with the Melody  valve as well as details of 
the implantation procedure have been described previously1-9.
Endpoints 
Primary endpoints of the study included a composite endpoint of TPVI-related follow-up events 
(i.e. death, reoperation or reintervention >48h after TPVI) and TPVI infective endocarditis 
according to modified Duke criteria (possible or definite) 10-13.
Secondary endpoints of the study included procedural complications of TPVI with the 
Melody™ valve 
invasive assessment of acute hemodynamic changes after TPVI and 
non-invasive follow-up assessment up to 10-14 months after TPVI (labelled ´1year´). Non-
invasive follow-up assessment was performed according to each institution's routine practice 
and not in a protocol-specified manner; no dates of assessment were recorded. Usually, patients 
were assessed within 1-3 months post-TPVI (labelled ´post´) and within 10-14 months after 
TPVI (labelled ´1year´). The exam techniques that were applied during the non-invasive 
follow-up assessment included echocardiography, clinical assessment (NYHA-class) and chest 
X-ray investigation; more detailed information on the non-invasive follow-up assessment is 
provided in the Supplemental Figure Legends. Presence of TPVI stent fractures were graded 
according to the stent fracture classification by Nordmeyer et al., with the known limitations of 
fracture identification within multiple stent frames15.
Data on the invasive assessment of acute hemodynamic changes was available for 635/845 
(75%) to 826/845 (98%) patients (Table 6); data on the non-invasive follow-up assessment was 
available for 413/845 (49%) to 781/845 (92%) patients (Supplemental Figure 4). Information 




































































Continuous data are expressed as mean ± SD or median with interquartile range (IQR) or range 
while categorical data are shown as absolute and relative frequencies (percentages). Continuous 
t tests or with Mann-Whitney U tests where 
appropriate. Kruskal-Wallis-test was applied to compare more than two groups. Categorical 
variables w 2
frequencies were < 5. For procedural complications, 95%-Confidence intervals (CI) of the 
observed relative frequencies were calculated using the method of Agresti-Coull16. Wilcoxon 
signed rank tests were performed to compare dependent data. For acute hemodynamic 
outcomes, 95%-CIs of the median of the differences between pre and post measurements were 
calculated using the ´Bias corrected and accelerated method´ or the ´bootstrap percentile 
method´ in case of computational errors using 10,000 resamplings17, 18.
Cumulative incidence functions were created to display the time-to-first event of the composite 
endpoint (i.e. TPVI-related death, reoperation and reintervention) and of TPVI infective 
endocarditis accounting for ´non-TPVI related death´ or ´non-TPVI right ventricular outflow 
tract obstruction (RVOTO)´ as competing risks. Starting point for the follow-up time was the 
day of intervention and follow-up times were summarized using median and range. Patients 
who underwent a TPVI-related reintervention with balloon dilation due to other reasons than 
TPVI infective endocarditis remained under follow-up for the assessment of TPVI infective 
endocarditis. For time-to-event outcomes, multivariable Cox proportional hazards models were 
created to calculate cause-specific hazards, and the assumptions of proportional hazards as well 
as goodness-of-fit were verified. Covariates for the multivariable models included calendar year 
of intervention, patient age and gender, primary hemodynamic lesion, pre-stenting, size of 
delivery system, and the invasively measured residual RV-to-PA pressure gradient (per 5 
mmHg). Further, linear regression was done to examine the relationship between original 



































































system). For all tests a P-value of <0.05 was considered statistically significant although results 
are to be considered as exploratory. Statistical analysis was performed on the SAS software 
(Version 9.4; SAS Institute Inc., Cary, NC, USA), R (Version 3.5.0 including the packages 





































































Patient characteristics   
Baseline data are presented in Table 1. Between December 2006 and September 2013, 845 
patients underwent TPVI with the Melody  valve (Supplemental Figure 1) and were   
followed-up for a median of 5.9 years (range 0 days to 11 years). Patients were enrolled from 
42 centres (Figure 1), of which 27 centres enrolled < 20 patients and 15 centres  20.  
Procedural details 
Details on the procedural variables are summarized in Table 2. Pre-stenting with at least one 
bare metal stent prior to TPVI was performed in the majority of patients (737/845, 87%). In 
patients who underwent TPVI with the Melody
(n=363), pre-stenting was used in 272/363 (74.9%) patients, whilst in the more current years 
(2010-2013; n=482), pre-stenting was used in 465/482 (96.5%) patients (P < 0.001).              
On average, the pre-stenting procedure added 28 minutes to the overall procedure time and 5 
minutes to the overall fluoroscopy time when compared to patients who underwent TPVI only 
(Supplemental Tables 1 and 2). Over half Melody  valves were implanted on a 22-mm 
Ensemble  delivery system (452/845, 53.5%). The relationship between the intended size of 
delivered TPVI (i.e. size of Ensemble  delivery system) and the original conduit diameter is 





































































The composite endpoint of TPVI-related death, reoperation and reintervention showed an 
incidence rate of 4.2% per person per year (95% CI 3.7-4.9). The corresponding cumulative 
incidence plot is presented in Figure 2.
Tabulated information on the composite endpoint events can be found in Supplemental Table 4.
A composite endpoint event occurred in 207/845 (24.5%) patients during follow-up: there were 
5/845 (0.6%) deaths due to fulminant endocarditis, 80/845 (9.5%) reoperations with TPVI 
explantation (TPVI infective endocarditis, n=53; , n=20; major 
TPVI stent fractures, n=6; chronic pericardial effusion, n=1) and 122/845 (14.4%) 
reinterventions (pulmonary re-stenosis, n=88; major TPVI stent fracture, n=18; TPVI infective 
endocarditis, n=16), of which 72/122 (59%) related to balloon dilation of TPVI and 50/122 
(41%) to repeat TPVI as ´valve-in-valve´ procedures.  
In a multivariable Cox proportional hazard model (Table 3), 4 covariates showed a statistically 
significant association to the composite endpoint of TPVI-related follow-up events: patient age 
(adjusted hazard ratio: 0.96, 95% CI 0.95 0.98; P = 0.0001), patient gender: female (adjusted 
hazard ratio: 0.67, 95% CI 0.49 0.93; P = 0.015), size of delivery system: 22-mm (vs. 18-mm) 
(adjusted hazard ratio: 0.59, 95% CI 0.41 0.86; P = 0.006) and residual RV-to-PA pressure 



































































TPVI infective endocarditis 
TPVI infective endocarditis (I.E.) showed an incidence rate of 2.3% per person per year (95% 
CI 1.9-2.8). The corresponding cumulative incidence plot is presented in Figure 3.
In the MELODY Registry, 109/845 (12.9%) patients had TPVI I.E.; of those, 68/109 (62%) 
were classified as definite and 41/109 (38%) as possible TPVI I.E. according to modified Duke 
criteria. In 100/109 (92%) patients, TPVI I.E. was blood-culture positive, whilst in 9/109 (8%) 
patients, TPVI I.E. was blood-culture negative. In the majority of patients with blood-culture 
positive TPVI I.E., Staphylococcal species were found (n=46/100, 46%; Supplemental Table 5).  
Details on the primary management of TPVI I.E. and secondary outcomes are displayed in 
Supplemental Figure 5. Primary management of TPVI I.E. included conservative management 
with medical therapy in 41/109 (38%) patients, reintervention and medical therapy in 15/109 
(14%) patients and reoperation with TPVI explantation and medical therapy in 53/109 (48%) 
patients. However, 9/109 (8%) patients died due to TPVI I.E. after conservative management 
(n=5), reintervention (n=2) and reoperation with TPVI explantation (n=2), respectively.  
The proportion of patients who underwent conservative therapy only was lower in patients with 
definite TPVI I.E. compared to those with possible TPVI I.E. according to modified Duke 
criteria (n=17/68, 25% versus n=19/41, 46%; P = 0.037). Furthermore, the proportion of 
patients who presented with hemodynamic instability or septic syndrome was higher in patients 
with definite TPVI I.E. compared to those with possible TPVI I.E. (n=25/68, 37% versus 
n=3/41, 7%; P = 0.002). Further information on the secondary outcomes in the subgroups of 
patients with possible and definite TPVI I.E. can be found in Supplemental Table 6.
In a multivariable Cox proportional hazard model (Table 4), one covariate showed a 
statistically significant association to the composite endpoint of TPVI infective endocarditis: 
residual RV-to-PA pressure gradient (per 5 mmHg) (adjusted hazard ratio: 1.19, 95% CI 1.07




































































Procedural complications  
Details on procedural complications are summarized in Table 5. Four patients (0.5%) died due 
to procedural complications (coronary compression, n = 3; fatal bleeding, n = 1). All other 
patients survived until discharge. Surgical or interventional treatment of a procedural 
complication was necessary in 10 (1.2%), and in 17 patients (2.0%), respectively. In 50 patients 
(5.9%), procedural complications could be managed conservatively.  
Invasive assessment of acute hemodynamic changes after TPVI  
Acutely, TPVI led to a significant reduction of the invasively measured peak RV-to-PA 
pressure gradient from 36 (IQR 24-47) to 12 (IQR 7-17) mmHg (P < 0.001). Subsequently, 
there was a significant reduction in the RV systolic pressure from 61 (IQR 50-73) to 40 (IQR 
34-49) mmHg and in the RV-to-systemic pressure ratio from 0.64 (IQR 0.5-0.8) to 0.37 (IQR 
0.3-0.5) (P < 0.001 for each). The PA diastolic pressure increased after TVPI from 10 (IQR 8-
13) to 13 (IQR 10-16) mmHg (P < 0.001). The overall data on acute hemodynamic outcomes 
with invasive pressure measurement are displayed in Table 6.
Non-invasive follow-up assessment up to ´1-year´ 
In a subset of patients, data on serial non-invasive follow-up assessment was available for 
review (Supplemental Figure 4). There was sustained echocardiographic outcome at the         
´1-year´ assessment when compared to early post-intervention (peak RVOT velocity: 2.58 ± 
0.69 vs. 2.61 ± 0.64 m/s, P = 0.001; pulmonary regurgitation grade >2: 1 vs. 1%; peak TR-jet 
velocity: 3.1 ± 0.7 vs. 3.0 ± 0.6 m/s, P = 0.16). Furthermore, the early improvement in NYHA-
class after TPVI was sustained at the ´1-year´ assessment. TPVI stent fractures led to 




































































The objective of the post-approval MELODY Registry was to obtain multicentre registry data 
after TPVI with the Melody  valve in a large-scale cohort of CHD patients.                 
Currently, ~350 patients undergo TPVI with the Melody  valve in Europe per year.            
The MELODY Registry included 845 patients from 42 cardiac centres and, thus, represents the 
largest post-approval cohort of patients after TPVI with the Melody  valve to date.  
Composite endpoint 
The composite endpoint of TPVI-related death, reoperation and reintervention showed an 
incidence rate of 4.2% per person per year (95% CI 3.7-4.9). In a multivariable Cox 
proportional hazard model, there was a strong association between the composite endpoint and 
the residual invasively measured RV-to-PA pressure gradient (per 5 mmHg) at the time of 
TPVI (adjusted hazard ratio: 1.21, 95% CI 1.12 1.30; P < 0.0001). These data suggest that one 
potential factor to reduce the risk of the composite endpoint could be to reduce the residual RV-
to-PA pressure gradient at the time of TPVI. However, further research is necessary to assess 
the potential benefit of reduced residual RV-to-PA pressure gradients during follow-up.  
When arguing for targeted gradient reduction during TPVI, however, the risks of coronary 
compression and conduit rupture related to more forceful TPVI expansion need to be 
considered. In the MELODY Registry, 26% of the stents that were used for pre-stenting were 
covered CP-stents (Supplemental Table 2). Furthermore, an increasing use of covered stents for 
pre-stenting is reported as an attempt to prevent from bleeding in case of conduit rupture during 
stent implantation. The increased use of covered pre-stents might have an influence on outcome 



































































Another variable that showed a statistically significant association with the composite endpoint 
on multivariable testing was the use of a 22-mm Ensemble  delivery system (vs. 18-mm: 
adjusted hazard ratio: 0.59, 95% CI 0.41 0.86; P = 0.006).  It could be hypothesized that in the 
MELODY Registry, 22-mm Ensemble  delivery systems were chosen more often in patients 
with  in relative terms  
RV-to-PA conduits (Supplemental Figure 3). However, further research is required to assess 
the potential benefits of this approach.  
TPVI infective endocarditis 
TPVI infective endocarditis (I.E.) showed an incidence rate of 2.3% per person per year     
(95% CI 1.9-2.8). This data is comparable to a previous study with pooled data from 311 
patients that showed an annualized I.E. rate of 2.4% after TPVI with the Melody  valve 11.
The clinical impact of TPVI I.E. was substantial in the MELODY Registry since it was 
associated with significant morbidity and 9 follow-up deaths. In the MELODY Registry, 
68/109 (62%) patients were classified as definite and 41/109 (38%) as possible TPVI I.E. 
according to modified Duke criteria10-13. Although in the MELODY Registry, patients with 
possible TPVI I.E. seemed to present with less severe disease compared to those who were 
classified as definite TPVI I.E., the clinical utility of the modified Duke criteria related to the 
diagnostic classification and prognostication of TPVI I.E. remains to be determined.                  
In particular, there are known limitations related to the visualization of 
to artifacts of the stent frame10, 11, which might impact on the sensitivity and specificity of one 
of the major modified Duke criteria (i.e. ´imaging positive for I.E.´). Thus, a revised clinical 
classification system for TPVI I.E. and longer follow-up might be useful to study this clinically 



































































In the majority of patients with blood-culture positive TPVI I.E., Staphylococcal species were 
found (n=46/100, 46%). TPVI I.E. with Staphylococcal species led to 7/9 (78%) of deaths that 
were attributed to TPVI I.E.. These findings are similar to previous findings that were obtained 
in an analysis of 76 unique published cases of endocarditis after TPVI with alve 
(Staphylococcal species: found in 47% cases, led to 8/9 (89%) deaths attributed to TPVI I.E.)13.
The findings of a multivariable Cox proportional hazard model suggest that one potential factor 
to reduce the risk of developing TPVI I.E. could be to reduce the residual RV-to-PA pressure 
gradient at the time of TPVI. However, further research is necessary to assess the potential 
benefit of reduced residual RV-to-PA pressure gradients. Because there is only limited 
knowledge about specific risk factors (e.g. discontinuation of antiplatelet therapy during 
follow-up) for the development of I.E. after TPVI10 as yet, patients should be strongly 
encouraged to apply general measures of endocarditis prevention (e.g. good dental hygiene). 
Furthermore, patients and medical personnel should be made aware of early signs of I.E. to 
allow for immediate treatment. 
Procedural complications 
Overall, major procedural complications (death, surgical or interventional treatment required) 
occurred in 4.2% in the MELODY Registry, which is comparable to previous studies including 
the expanded FDA Melody  valve trial3, 8. Coronary compression after TPVI19, 20 occurred in 
five patients (0.6%) leading to procedure-related death in three patients (0.35%) and emergency 
surgery in two patients (0.25%). Importantly, three patients after previous Ross-procedure 
suffered from coronary compression; these patients are already known to have a high risk for 
this major complication after TPVI20. Although the risk of coronary compression can be 
evaluated by thorough assessment prior to TPVI, it cannot be avoided completely. When high-
pressure pre-dilation of the intended implantation site is performed, there is a risk of conduit 
rupture that needs to be considered. In the MELODY Registry, the incidence of fatal conduit 




































































Acutely, TPVI with the Melody  valve led to a significant reduction of the RV-to-PA pressure 
gradient and to a complete restoration of pulmonary valve function. These hemodynamic 
outcomes were sustained at ´1-year´ assessment, which is in line with previous studies3, 8, 21, 22
confirming the hemodynamic efficacy of TPVI with the Melody  valve.  
Limitations
The most important limitations are the retrospective nature of the registry with self-reporting of 
data; furthermore, there was no auditing of data. Although the completeness of data on the 
primary endpoint parameters (i.e. composite endpoint and TPVI I.E.) was 100%, there was 
limited completeness of data on the secondary endpoint parameters, particularly for the       
non-invasive follow-up assessment.  
Conclusions
The post-approval MELODY Registry confirms the efficacy of TPVI with the Melody  valve 
in a large-scale cohort of CHD patients. The composite endpoint of TPVI-related death, 
reoperation and reintervention showed an incidence rate of 4.2% per person per year (95% CI 
3.7 4.9). The residual invasively measured RV-to-PA pressure gradient may serve as a target 
for further improvement in the composite endpoint and TPVI infective endocarditis (I.E.). 
However, TPVI I.E. remains a concern; TPVI I.E. showed an incidence rate of 2.3% per person 
per year (95% CI 1.9 2.8) and resulted in significant morbidity and mortality; therefore, 
patients should be strongly encouraged to apply general measures of endocarditis prevention 
(e.g. good dental hygiene). Furthermore, patients and medical personnel should be made aware 
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Figure 1. Geographical distribution of the study centres, including color-coding of the sample 
size per study centre. 
Figure 2.  Cumulative incidence plot of the composite endpoint of TPVI-related death, 
reoperation and reintervention. At 6 years the cumulative incidence of the composite endpoint 
was 20.8% (95% CI 19.1-22.8), and at 8 years the cumulative incidence of the composite 
endpoint was 28.4% (95% CI 25.6-31.4). 
Figure 3.  Cumulative incidence plot of TPVI infective endocarditis. At 6 years the cumulative 
incidence of TPVI infective endocarditis was 11.4% (95% CI 10.3-12.5), and at 8 years the 







































































Age at TPVI (years), mean ± SD 21.0 ± 11.1 
Sex (female / male), n (%) 280 / 565 (33 / 67) 
Height (cm), mean ± SD 161 ± 17 
Weight (kg), mean ± SD 59 ± 21 
Primary hemodynamic lesion, n (%)
Predominant pulmonary stenosis (PS)a                                     458/845 (54) 
Predominant pulmonary regurgitation (PR)b 182/845 (22) 
Mixed lesionc                                                                       205/845 (24) 
Principal diagnosis, n (%)
Tetralogy of Fallot (TOF) 263/845 (31) 
Pulmonary atresia with VSD 154/845 (18) 
Truncus arteriosus communis 92/845 (11) 
TGA, pulmonary stenosis (PS), VSD 80/845 (9) 
Aortic valve disease, status post Ross-operation 164/845 (20) 
Double outlet right ventricle (DORV) with PS 34/845 (4) 
Other / unknown 58/845 (7) 
Number of previous surgeries, median (range) 2 (0 to 6) 
Right ventricular outflow tract (RVOT), n (%)
Native or patch-extended RVOT 46/845 (6) 
Homograft conduit 567/845 (68) 
Heterograft conduit  92/845 (11) 
Bioprosthetic heart valve (stented) 61/845 (7) 
Other / unknown 79/845 (8) 
Original conduit diameter 
Homograft or heterograft conduits, mean ± SD (mm) 20.3 ± 3.2 
n (%) 178/659 (27) 
         18-22 mm, n (%) 271/659 (41) 
         >22 mm, n (%) 142/659 (22) 
         unknown, n (%) 68/659 (10) 



































































VSD, ventricular septal defect; TGA, transposition of the great arteries.  
aPredominan and pulmonary 
regurgitation < 'moderate' on echocardiography; bpredominant pulmonary regurgitation (PR), 
peak RVOT velocity <3,5 m/s and pulmonary regurgitation > 'moderate' on echocardiography; 



































































Table 2. Procedural variables 
Procedural variables
Overall population 
(n = 845) 
Procedure time (min), mean ± SD 152 ± 56 
Fluoroscopy time (min), mean ± SD 32 ± 19 
Vascular access route, n (%)
Trans-femoral 805/845 (95) 
Trans-jugular 36/845 (4.5) 
Other / unknown 4/845 (0.5) 
Assessment of the relationship between coronary anatomy and RVOT, n (%)
          Performed prior to the TPVI catheterization procedure 87/845 (11) 
          Performed during the TPVI catheterization procedure 758/845 (89) 
                  Assessment with only one modality 345/758 (46) 
                  Assessment with combinations of modalities 413/758 (54) 
Modalities used for assessment, n (%) 
        Aortic root angiography 642/758 (85) 
        Selective coronary angiography (SCA) 392/758 (52) 
                  SCA plus balloon inflation in RVOTa 281/758 (37) 
Balloon sizing of RVOT, n (%) 289/845 (34) 
High-pressure pre-dilation of RVOT, n (%) 405/845 (48) 
Pre-Stenting prior to TPVI, n (%)
No pre-stent 108/845 (13) 
1 pre-stent 555/845 (66) 
2 pre-stents 148/845 (17) 
3 pre-stents 34/845 (4) 
Size of Ensemble delivery system (EDS) for TPVI, n (%)
18-mm 156/845 (18) 
20-mm 237/845 (28) 
22-mm 452/845 (54) 
High-pressure post-dilation of TPVI, n (%) 540/845 (64) 



































































RVOT, right ventricular outflow tract. aIt is of note that during high-pressure balloon dilation of 
RVOT and SCA, no data was recorded whether the high-pressure balloon was inflated to the 
predefined maximal diameter. bAdditional procedures during catheterization, e.g. balloon 


































































Table 3. Cox regression model related to the composite endpoint of TPVI-related death, reoperation and reinterve
Variable Coefficient Standard error 
Hazard ratio 
exp(coefficient) 
Calendar year of TPVI procedure* -0.10 0.05 0.91
Patient age [years] -0.04 0.01 0.96
Patient gender: Female (vs. Male) -0.40 0.16 0.67
Lesion: Predominant PR (vs. predominant PS) 0.15 0.20 1.16
Lesion: Mixed (vs. predominant PS) -0.05 0.18 0.95
Prestenting: Yes (vs. No) -0.31 0.19 0.73
Size of delivery system: 20-mm (vs. 18-mm) -0.29 0.20 0.75
Size of delivery system: 22-mm (vs. 18-mm) -0.52 0.19 0.59
Residual RV-to-PA pressure gradient [per 5 mmHg] 0.19 0.04 1.21
*2006-2013. Significant differences in bold. 
Test for proportional hazard assumption: P = 0.088 




















































Table 4. Cox regression model related to TPVI infective endocarditis 
Variable Coefficient Standard error 
Hazard ratio 
exp(coefficient) 
Calendar year of TPVI procedure* 0.09 0.07 1.10
Patient age [years] -0.01 0.01 0.99
Patient gender: Female (vs. Male) 0.03 0.21 1.03
Lesion: Predominant PR (vs. predominant PS) 0.20 0.26 1.22
Lesion: Mixed (vs. predominant PS) 0.01 0.24 1.01
Prestenting: Yes (vs. No) 0.00 0.30 1.00
Size of delivery system: 20-mm (vs. 18-mm) -0.20 0.29 0.82
Size of delivery system: 22-mm (vs. 18-mm) -0.27 0.27 0.76
Residual RV-to-PA pressure gradient [per 5 mmHg] 0.17 0.05 1.19
*2006-2013. Significant differences in bold. 
Test for proportional hazard assumption: P = 0.189 


























































n (% of n=845; 95% CI) n (% of n=845; 9
Coronary compression 5 (0.6; 0.21-1.42) 0 (0; 0-0.55) 0 (0; 0-0.55) 
Bleeding due to conduit rupture 7 (0.8; 0.36-1.74) 0 (0; 0-0.55) 6 (0.7; 0.29-1.58) 
Bleeding due to pulmonary artery 5 (0.6; 0.21-1.42) 1 (0.1; 0-0.74) 3 (0.4; 0.07-1.09) 
Pre-stent dislodgment 2 (0.2; 0.01-0.92) 1 (0.1; 0-0.74) 1 (0.1; 0-0.74) 
TPVI dislodgment 3 (0.4; 0.07-1.09) 0 (0; 0-0.55) 1 (0.1; 0-0.74) 
Obstruction of pulmonary artery 1 (0.1; 0-0.74) 0 (0; 0-0.55) 1 (0.1; 0-0.74) 
Balloon rupture 13 (1.6; 0.87-2.64) 10 (1.2; 0.61-2.20) 3 (0.4; 0.07-1.09) 
Vascular access complications 22 (2.6; 1.70-3.93) 18 (2.1; 1.33-3.37) 1 (0.1; 0-0.74) 
Arrhythmia 15 (1.8; 1.05-2.93) 15 (1.8; 1.05-2.93) 0 (0; 0-0.55) 
Othera 8 (0.9; 0.45-1.89) 5 (0.6; 0.21-1.42) 1 (0.1; 0-0.74) 
Overall 81 (9.6; 7.77-11.77) 50 (5.9; 4.5-7.73) 17 (2.0; 1.24-3.22) 
aOther, e.g. dislocation of pacemaker / ICD-leads, injury of a right ventricular papillary muscle, pulmonary em




















































Table 6. Acute hemodynamic outcome in the overall cohort, invasive pressure measurements 
 Pre post Median diff
Parameter 
median (IQR) 
[n; % of n = 845] 
median (IQR)
[n; % of n = 845
RVa systolic pressure (mmHg) 
61 (50; 73)  
[n= 826; 98%]




PAb systolic pressure (mmHg) 
24 (20; 30) 
[n=825; 98%] 
28 (23; 34) 
[n=781; 92%] 
3 (-1; 8) 
[n=771; 91%]
PA diastolic pressure (mmHg)
10 (8; 13) 
[n=816; 97%] 
13 (10; 16) 
[n=678; 80%] 
3 (0; 5) 
[n=666; 79%]
RV-to-PA pressure gradient (mmHg) 
36 (24; 47) 
[n=821; 97%] 




Systemic systolic pressure (mmHg) 
94 (85; 106) 
[n=751; 89%] 
108 (95; 121) 
[n=663; 78%] 
11 (0; 24) 
[n=649; 77%]
RV-to-systemic pressure ratio 
0.64 (0.5; 0.8) 
[n=747; 88%] 




aRV, right ventricle; bPA, pulmonary artery. The 95% confidence intervals (CI) correspond to bias-corrected
































































Procedure time (min), mean ± SD 128 ± 46 156 ± 56 <0.001
Fluoroscopy time (min), mean ± SD 28 ± 13 33 ± 20 0.01
Size of Ensemble delivery system (EDS) for TPVI, n (%) 0.86
18-mm 22/108 (20) 134/737 (18) 
20-mm 30/108 (27) 207/737 (28) 
22-mm 56/108 (51) 396/737 (54) 
Ratio of EDS size to original conduit diameter, mean ± SD 0.98 ± 0.11 1.05 ± 0.18 <0.001
High-pressure post-dilation of TPVI, n (%) 78/108 (71) 462/737 (64) 0.14
Significant differences in bold.  
2
Supplemental Table 2. Stent types used for pre-stenting prior to TPVI 
Stent types used for pre-stenting 
Number of 
 implanted pre-stents 
(n=953)
CP-Stent (NuMed), uncovered, n (%) 241/953 (25) 
CP-Stent (NuMed), covered, n (%) 251/953 (26) 
IntraStent MaxLD (ev3), n (%) 237/953 (25) 
AndraStent (Andramed), n (%) 63/953 (7) 
Other / unknown, n (%) 161/953 (17) 
3
Supplemental Table 3. Details on pre-TPVI assessment of the anatomical relationship between 
the course of the coronary arteries and the RVOT in the five patients who suffered from 
coronary compression during TPVI 
Parameter Outcome 




SCA plus balloon 
inflation in RVOT 
Patient No. 1 Reoperation TOF Yes Yes Yes 
Patient No. 2 Reoperation s/p Ross-Operation Yes Yes No
Patient No. 3 Death s/p Ross-Operation No No Yes 
Patient No. 4 Death TGA, VSD, PS Yes Yes No
Patient No. 5 Death s/p Ross-Operation Yes No No
RVOT, right ventricular outflow tract; TOF, Tetralogy of Fallot; TGA, transposition of the 
great arteries; VSD, ventricular septal defect; PS, pulmonary stenosis.  
4
Supplemental Table 4.  Details on the events for the ´time-to-first event´ analyses 
Event specification and reason for event n (%) 
TPVI-related reintervention, n (%) 122/845 (14.4) 
           Balloon dilation of TPVI, n (%) 72/122 (59) 
                         Pulmonary restenosis 62/72 (86) 
                         TPVI infective endocarditis 8/72 (11) 
               TPVI stent fractures  2/72 (3) 
           Repeat TPVI as ´valve-in-valve´ procedure, n (%) 50/122 (41) 
                         Pulmonary restenosis 26/50 (52) 
                         TPVI infective endocarditis 8/50 (16) 
               TPVI stent fractures  16/50 (32) 
TPVI-related reoperation with explantation of TPVI, n (%) 80/845 (9.5) 
                         Pulmonary restenosis 20/80 (25) 
               TPVI infective endocarditis 53/80 (67) 
               TPVI stent fractures 6/80 (7) 
               Chronic pericardial effusion 1/80 (1) 
TPVI-related death, n (%) 5/845 (0.6) 
                         TPVI infective endocarditis 5/5 (100) 
Supplemental Table 5. Secondary outcomes of TPVI infective endocarditis (n=109), stratified by infectious orga
Number of patients, n (%) Conservative:  medical therapy, n (%) Reintervention, n
Blood-culture negative 9/109 (8) 1/9 (11) 2/9 (22) 
Blood-culture positive 100/109 (92) 35/100 (35) 11/100 (11) 
Staphylococcal species 46/100 (46) 10/46 (22) 4/46 (9) 
Streptococcal species 32/100 (32) 15/32 (47) 4/32 (13) 
    HACEK organisms 9/100 (10) 5/9 (56) 2/9 (22) 
    Corynebacterium 2/100 (2) 1/2 (50) 0/2 (0) 
    Rothia dentocariosa 1/100 (1) 0/1 (0) 0/1 (0) 
    Neisseria elongate 1/100 (1) 0/1 (0) 0/1 (0) 
    Abiotrophia defective 1/100 (1) 1/1 (100) 0/1 (0) 
    Coxiella burnetii 1/100 (1) 0/1 (0) 0/1 (0) 
    Fungus 1/100 (1) 0/1 (0) 1/1 (100) 
        Other species / unknown 6/100 (6) 3/6 (50) 0/6 (0) 
Supplemental Table 6. Secondary outcomes of TPVI infective endocarditis (n=109), divided by the subgro
according to modified Duke criteria                                  
Total possible TPVI I.E. 
Number of patients, n (%) 109/109 (100) 41/109 (38) 
Secondary outcomes 
   Conservative:  medical therapy, n (%) 36/109 (33) 19/41 (46) 
   Reintervention, n (%) 13/109 (12) 5/41 (12) 
   Reoperation, n (%) 51/109 (47) 15/41 (37) 
   Death, n (%) 9/109 (8) 2/41 (5) 
Secondary outcomes
Conservative: medical therapy, n (%) 36/109 (33) 19/41 (46) 
Reintervention, reoperation or death, n (%) 73/109 (67) 22/41 (54) 
Hemodynamic instability or septic syndrome
Present, n (%) 28/109 (19) 3/41 (7) 
Not present, n (%) 88/109 (81) 38/41 (93) 
Significant differences in bold.
Legends 
Supplemental Figure 1. Flow chart of patient selection with step-by-step exclusion of datasets 
according to predefined criteria.  
Supplemental Figure 2. Number of included patients per calendar year. In this figure, two 
´eras´ can be identified within the MELODY Registry cohort. Between the years 2006 and 
steep increase of included patients (i.e. first era); this increase was followed by a phase with 
stable number of included patients between 2010 and 2013 (i.e. more current era). 
Supplemental Figure 3. The relationship between the intended size of delivered TPVI (i.e. size 
of Ensemble delivery system) and the original conduit diameter are displayed in violin plots, 
which resemble a combination of Box and distribution plots. For each intended size of 
delivered TPVI (i.e. size of Ensemble delivery system 18, 20 and 22 mm, respectively) the 
corresponding distribution of original conduit diameters are plotted. The green boxes 
correspond to the Inter-quartile-range (IQR) and the bold black line to the median of the 
respective values. This is shown for homograft and heterograft conduits (left panel) and for 
bioprosthetic heart valves (right panel). The fine black line corresponds to the equation of x = y, 
where the intended size of the delivered TPVI would exactly correspond to the original conduit 
diameter. Any point that lies below the black line would correspond to a scenario, where the 
intended size of the delivered TPVI would be greater than the original conduit diameter (TPVI 
> conduit). Any point that lies above the black line would correspond to a scenario, where the 
intended size of the delivered TPVI would be smaller than the original conduit diameter (TPVI 
< conduit). The bold dashed red lines relate to linear regression functions that describe the 
average relationships between the intended size of the delivered TPVI and the original conduit 
diameter (in patients with homograft or heterograft conduits: 0.75*x + 4.9, R2=0.13; in patients 
with bioprosthetic heart valves: 0.96*x + 1.55, R2=0.22). In case of homograft or heterograft 
conduits, that line illustrates that, when 20 mm and 22 mm Ensemble delivery systems were 
used, the intended size of delivered TPVI was chosen larger  on average  than the original 
of delivered TPVI was chosen smaller  on average  than the original diameters of the 
bioprostheses (i.e
Supplemental Figure 4. A, B, C: echocardiographic outcomes pre, post and 1-year after TPVI 
in a subset of patients in whom corresponding data was available for review (A: peak RVOT 
velocity (m/s), B: peak TR-jet velocity (m/s), C: pulmonary regurgitation (PR) grade). During 
echocardiography, the peak velocities across the right ventricular outflow tract (RVOT) and the 
tricuspid regurgitation (TR) jet were obtained from continuous-wave Doppler traces. Color 
flow Doppler mapping of the RVOT and branch pulmonary arteries was used for qualitative 
grading of pulmonary regurgitation (PR) from grade 0 (= none) to grade 4 (= severe). If 
presence of diastolic flow reversal in the main or branch pulmonary arteries was seen, PR was 
graded > 2. D: NYHA-class pre, post and 1-year after TPVI. The black boxes with error bars 
(standard deviations) correspond to the overall patient cohort, whilst the colored boxes 
correspond to the mean values stratified according to the primary hemodynamic lesion (A and 
B).
Supplemental Figure 5. Details on the primary management of TPVI infective endocarditis 
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Abstract 
Aims  The post-approval MELODY Registry aimed to obtain multicentre registry data after 
transcatheter 
large-scale cohort of patients with congenital heart disease (CHD). 
Methods and results  Retrospective analysis of multicentre registry data after TPVI with the 
. 845 patients (mean age: 21.0±11.1 years) underwent TPVI in 42 centres between 
12/2006 and 09/2013 and were followed-up for a median of 5.9 years (range: 0 to 11.0 years). The 
composite endpoint of TPVI-related events during follow-up (i.e. death, reoperation or 
reintervention >48h after TPVI) showed an incidence rate of 4.2% per person per year (95% CI 
3.7 4.9). TPVI infective endocarditis showed an incidence rate of 2.3% per person per year (95% 
CI 1.9 2.8) and resulted in significant morbidity and in 9 deaths. In multivariable Cox 
proportional hazard models, the invasively measured residual RV-to-PA pressure gradient (per 5 
mmHg) was associated with the risk of the composite endpoint (adjusted hazard ratio: 1.21, 95% 
CI 1.12 1.30; P < 0.0001) and the risk of TPVI infective endocarditis (adjusted hazard ratio: 1.19, 
95% CI 1.07 1.32; P = 0.002).  Major procedural complications (death, surgical or interventional 
treatment requirement) occurred in 0.5, 1.2, and 2.0%, respectively. Acutely, the right ventricle 
(RV)-to-pulmonary artery (PA) pressure gradient and the percentage of patients with pulmonary 
regurgitation grade >2 improved significantly from 36 (interquartile range 24-47) to 12 
(interquartile range 7-17) mmHg and 47 to 1%, respectively (P < 0.001 for each). 
Conclusions  The post-approval MELODY Registry confirms the efficacy of TPVI with the 
-scale cohort of CHD patients. The residual invasively measured RV-to-
PA pressure gradient may serve as a target for further improvement in the composite endpoint and 
TPVI infective endocarditis. However, TPVI infective endocarditis remains a significant concern 
causing significant morbidity and mortality.  
